Cigna Claims BMS Tied Revlimid Settlements to Pomalyst ‘Pay-for-Delay’ Scheme

Purchasers Overpaid ‘By Millions If Not Billions’ For Pomalyst, Antitrust Suit Alleges

Among other schemes, Cigna alleges that Celgene and parent Bristol Myers Squibb “paid” generic challengers – via lucrative Revlimid profit-sharing agreements – to delay generic market entry for Pomalyst until 2026, unlawfully extending their monopoly and overcharging purchasers.

• Source: Alamy
Key Takeaways
  • Cigna has filed an antitrust lawsuit against Bristol Myers Squibb and its subsidiary Celgene, alleging that they unlawfully extended the monopoly on the cancer drug Pomalyst (pomalidomide) through illegal ‘pay-for-delay’ tactics.

Bristol Myers Squibb’s Celgene defrauded the US Patent Office, filed baseless lawsuits and used illicit reverse-payment settlements to “unlawfully extend,...

More from Legal & IP

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By 

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Alchem Fined Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

More from Products